Verve Therapeutics

Verve Therapeutics

  • Founded: 2019
  • Location: Cambridge, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin1
  • Therapy area: Heterozygous familial hypercholesterolemia
  • Drug types: CVV, GEN, HEP
  • Lead product: VERVE-101
  • Product link:
  • Funding: $307M IPO Jun 2021; $94M B Jan 2021; $63M A2 Jun 2020; $58.5M A May 2019

job board

Short description:

Gene-editing Treatments

Drug notes:

VERVE-201 Clin0 familial hypercholesterolemia; 3 add'l products RD atherosclerotic cardiovascular disease/liver disease

Long description:

Verve Therapeutics is developing novel gene editing therapies for the treatment of cardiovascular diseases. The company has a proprietary platform for the development of base editors, which are enzymes that can make precise changes to DNA without causing harmful off-target edits. Base editors are a new class of gene editing tools that have the potential to revolutionize the treatment of genetic diseases. Unlike traditional gene editing tools, such as CRISPR/Cas9, base editors can make precise changes to a single nucleotide in DNA without causing harmful off-target edits. This makes base editors a safer and more effective tool for gene editing. Verve Therapeutics is using its proprietary base editor platform to develop therapies for a variety of cardiovascular diseases, including hypercholesterolemia and sickle cell disease.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy